Introduction: Hyperprolactinemia is a common side-effect of antipsychotic treatment. Antipsychotics and hyperprolactinemia are both considered risk factors of metabolic disturbances and diabetes. Investigations on prolactin response to meal ingestion in antipsychotic-treated patients are missing. Material and methods: In a case-control design, 49 antipsychotic-treated, clinically stable, nondiabetic, schizophrenia spectrum male patients were compared with 93 healthy male controls by age (33.1, SD 7.4 vs. 32.9, SD 6.6 years), body mass index (26.2, SD 4.6 vs. 26.1, SD 3.9 kg/m 2 ) and waist circumference (96.4, SD 13.0 vs. 96.7, SD 11.9 cm). Serum-prolactin was measured in the morning and 90 min after ingestion of a standardized liquid meal (2268 kJ).
Introduction
The introduction of antipsychotic medication has indisputably improved the clinical outcome of patients with schizophrenia and related psychotic disorders, but the treatment is frequently associated with side-effects. Whereas the management of extra-pyramidal and metabolic side-effects has attracted considerable clinical attention, hyperprolactinemia is a common, but less investigated side-effect of antipsychotic treatment.
Prolactin is a pituitary hormone involved in reproduction, endothelial function, immune modulation, hair, skin and bone regulation, and metabolism (Marano and BenJonathan, 2014) . Prolactin is secreted in a circadian rhythm with approximately 19 pulses in 24 h and peaks during sleep (Roelfsema et al., 2012) . Due to circadian variation, serum prolactin is normally sampled between 0800 h and 1000 h. Prolactin level <20-25 ng/ml is considered normal, regardless of variations between assays, gender differences (women > men), and elevations associated with increased body weight (Roelfsema et al., 2012) .
Antipsychotics and hyperprolactinemia are both risk factors of metabolic disturbances and diabetes (Arslan et al., 2014; Yavuz et al., 2003) , but to what extent prolactin levels are associated with food intake in antipsychotic-treated patients is unknown. Previous reports on the physiological prolactin response to meal ingestion are scarce, small, and results are conflicting, possibly also reflecting differences in nutrition content between studies. The hitherto largest study in 20 healthy volunteers recently showed that prolactin decreases after meal ingestion (Plumelle et al., 2014) , but earlier studies have reported both unchanging (Goettler et al., 1990) , and increasing levels (Carlson et al., 1983; Ishizuka et al., 1983) .
The clinical effect as well as the extrapyramidal sideeffects of antipsychotic drugs are linked to the degree of dopamine D 2 receptor blockade in striatum (Kapur and Seeman, 2001 ). In the pituitary, blockade of the dopamine D 2 receptors leads to an increased release of prolactin resulting in clinical hyperprolactinemia (Meltzer and Fang, 1976) . Since the anterior pituitary gland is located outside of the blood brain barrier, especially antipsychotics with low lipophilicity, high peripheral-to-central dopamine D 2 receptor occupancy ratio, and high dopamine D 2 receptor affinity, e.g. perphenazine, risperidone, and amisulpride are prone to induce hyperprolactinemia (McKeage and Plosker, 2004) .
Conversely, treatment with aripiprazole, quetiapine, and clozapine is associated with lower risk of hyperprolactinemia, while ziprasidone and olanzapine appear to assume an intermediate position (Leucht et al., 2013) .
Here we investigate fasting and postprandial serum prolactin levels in a sample of non-diabetic antipsychotictreated male patients and matched healthy controls. Associations between prolactin levels and high, intermediate and low prolactinogenic antipsychotic treatment are explored.
Methods
The study was approved by the Committee on Biomedical Research Ethics for the Capital Region of Denmark (H-C-2007-0069), the Danish Data Protection Agency, and the Danish Medicines Agency (2602-706). The study was registered at ClinicalTrials.gov (NCT00627757), conducted in accordance with the Declaration of Helsinki II, carried out according to Good Clinical Practice (GCP), and monitored by the GCP of Unit Copenhagen University Hospital. Participants received written and verbal information about the study and gave written informed consent prior to enrollment.
Participants
We included 49 antipsychotic-treated, clinically stable, nondiabetic male patients and 93 healthy male controls in the age of 18-45 years. Details of inclusion and exclusion criteria and participants were previously reported (Ebdrup et al., 2014) . In short, patients had a diagnosis in the schizophrenia spectrum [ICD-10 diagnosis: F20, F21, F22, F25, F28, F60.1] and all were Caucasian outpatients treated with at least one antipsychotic. Controls were recruited by advertisement and were matched on age, body mass index (BMI), waist circumference, and race.
Based on the assumed prolactinogenic effect of the antipsychotic treatment (Leucht et al., 2013; McKeage and Plosker, 2004) , we divided patients into three subgroups: a high (perphenazine, amisulpride, risperidone) (n = 7), an intermediate (olanzapine, ziprasidone) (n = 14), and a low prolactinogenic subgroup (aripiprazole, clozapine, quetiapine) (n = 25). Six patients, who were treated with more than one antipsychotic drug, were excluded from the subgroup analyses.
Experimental procedures
Subjects were fasting as well as tobacco and alcohol abstinent for at least 8 h prior to baseline blood sampling, which was performed between 0730 h and 1030 h. After baseline sampling, each subject received a 360 ml liquid meal (66.2 g carbohydrates, 21.6 g proteins and 20.9 g fat [2268 kJ]; Nutricia Nutridrink, Nutricia A/S, Allerød, Denmark) over 10 min. Postprandial blood samples were collected after 90 min and plasma was stored at −80
• C until analyses.
Analyses
Prolactin was measured with a chemiluminescence immunoassay on Immulite 2500 instrument using L5KPR2 reagents (Siemens, Deerfield, IL, USA) calibrated toward WHO 3rd IS 84/500 with maximal intra and inter-assay variation coefficients of 3.6-7.4% and a limit of detection of 0.05 ng/ml according to the manufacturer's specifications.
Statistics
Group comparisons for demographic data were performed using independent t tests for continuous variables and Chisquare tests for nominal or ordinal variables. Prolactin values required logarithmic (log) transformation to obtain normal distribution. We tested for main effects between patients and controls with a repeated measures analysis of variance (rmANOVA). We entered 'Group' (patient vs. control) as between subject factor and 'Meal' (fasting vs. postprandial prolactin values) as within subject factor. Similarly, our subgroup analyses were done with rmANOVA.
Bonferroni post hoc analyses of significant main effects were performed with separate t tests. All statistical tests were two-tailed and a significance level of 0.05 was applied throughout. Data were analyzed using Statistical Package for the Social Science software (SPSS version 19, IBM Corporation, Armonk, NY, USA).
Results

Demographics
Patients and controls were males, well-matched on age (33.1, SD 7.4, vs. 32.9, SD 6.6 years, [range: 19-45 years]; p = 0.87), BMI (26.2, SD 4.6 vs. 26.1, SD 3.9 kg/m 2 ; p = 0.87), and waist circumference (96.4, SD 13.0 vs. 96.7, SD 11.9 cm; p = 0.43). Patients and controls did not differ significantly in glycated hemoglobin (HbA1c) (5.6, SD 0.3 vs. 5.7, SD 0.3%; p = 0.68). More patients were smokers (53 vs. 22%; p < 0.001), and patients were less physically active (<30 min/day) (33 vs. 5%; p < 0.001) (see Ebdrup et al., 2014 for details) .
There were no significant differences in age, BMI or waist circumference between the three patient subgroups and controls.
Prolactin
The rmANOVA showed a main effect of Group [F 1, 140 The mean fasting prolactin levels did not differ significantly between patients and controls (12.33, SD 11.58 ng/ml, [range: 0.9-53.4 ng/ml] vs. 10.06, SD 8.67 ng/ml, [range: 2.2-66.0 ng/ml], t = 0.49; p = 0.62). Mean postprandial prolactin levels were significantly higher in patients compared to controls (14.95, SD 13.32 ng/ml vs. 7.64, SD 3.88 ng/ml, t = 3.3; p = 0.002). This group difference at the postprandial time point was explained by a trend-level significant increase in prolactin in patients ( 2.62, SD 10.96 ng/ml, t = −1.78, p = 0.081), along with a significant postprandial prolactin reduction in controls ( −2.53, SD 9.75 ng/ml, t = 2.45, p = 0.016) (Fig. 1) .
The mean fasting and postprandial prolactin levels in the three antipsychotic treatment subgroups were: 24.62, SD 18.35 and 30.08, SD 19.24 ng/ml (high prolactinogenic subgroup), 11.22, SD 10.02 and 18.56, SD 13.73 ng/ml (intermediate prolactinogenic subgroup), and 8.68, SD 5.02 and 8.72, SD 5.15 ng/ml (low prolactinogenic subgroup). Thus, the postprandial compared to the fasting prolactin levels were 22% higher in the high prolactinogenic subgroup, 65% higher in the intermediate prolactinogenic subgroup and unchanged in the low prolactinogenic subgroup.
The rmANOVA showed a main effect of Subgroup [ Post hoc tests of the fasting state revealed a significant difference between high vs. low (t = 2.824, p = 0.009), and high vs. control (t = 3.173, p = 0.002). Post hoc tests of the postprandial state showed significant differences between high vs. low (t = 4.106, p < 0.001), high vs. control (t = 6.505, p < 0.001), intermediate vs. low (t = 2.914, p = 0.006), and intermediate vs. control (t = 4.932, p < 0.001) (Fig. 2) .
Controlling for the variables, which we previously reported significantly different between patients and controls (tobacco smoking, daily physical activity, as well as fasting values of proinsulin, C-peptide, and glucosedependent insulinotropic polypeptide (GIP), total cholesterol, low-density lipoprotein cholesterol, triglycerides, and CRP, and postprandial values of insulin, proinsulin, Cpeptide, and GIP (Ebdrup et al., 2014) ), did not alter the findings.
Discussion
The present study supports that a decrease in serum prolactin appears to be a physiological response to meal ingestion (Plumelle et al., 2014) . Conversely, this response appears absent in antipsychotic-treated males, where serum prolactin levels either remain stable or increase depending on the prolactinogenic effect of the antipsychotic compound ( Figs. 1 and 2 ).
Fasting prolactin levels were similar in patients and controls, though somewhat lower than in a previous Figure 1 shows serum prolactin levels at fasting state and 90 min postprandially in patients and controls. Horizontal black bars represent mean prolactin levels. * Meal ingestion significantly reduced the prolactin level in controls (p = 0.016). ** Mean postprandial prolactin levels were significantly higher in patients compared to controls (p = 0.002).
report on fasting prolactin in antipsychotic-treated patients (18 ng/ml) (Suzuki et al., 2013) . This discrepancy may be explained by the relatively few of our patients on high prolatinogenic antipsychotics (15%), whereas the intermediate (37%) and particularly the low (54%) prolatinogenic groups were larger. Accordingly, the absence of significant differences in fasting prolactin levels between subgroups may therefore reflect a type 2 error in these analyses. Nevertheless, we observed significantly elevated fasting prolactin levels in patients treated with high prolatinogenic compounds compared to patients treated with low prolatinogenic compounds and between controls.
Our data and subgroup analyses indicate a hierarchical effect of antipsychotics on prolactin levels: The higher the prolatinogenic liability of an antipsychotic compound, the higher the fasting level of prolactin. Although the prolactin increase was more marked with intermediate (65%) than with high prolactinogenic compounds (22%), the prolactin levels significantly and hierarchically separated at the postprandial time point (Fig. 2) .
Some limitations apply to this study. Since fasting prolactin was sampled at only one time point, we could not control for fluctuations in the diurnal cycle of prolactin (Plumelle et al., 2014) . Assessment of individual diurnal variations would require fasting measurements at several time points, and to our knowledge, no studies have addressed this issue. Theoretically, our observed prolactin differences at 90 min could therefore reflect abnormal antipsychotic-induced diurnal variations rather than effects of meal. However, we would expect dyssynchronized prolactin secretion to affect prolactin levels at any time point. Since fasting prolactin levels did not differ between groups, our data favors the interpretation that diurnal variations is reflected in the marked inter-individual variations. Conversely, meal ingestion appears to drive the observed postprandial intra-individual group differences. With a half-life of approximately 40 min (Yoshida et al., 1991) , we judge 90 min appropriate to observe changes in prolactin. The fact that both patients and controls were examined in the morning and under identical conditions, and the clear hierarchical effect of prolactinogenic antipsychotic compounds on postprandial prolactin levels at the postprandial time point (Fig. 2) , support that we observe pharmacological effects rather than merely diurnal variations. Due to gender variations in prolactin secretion (Roelfsema et al., 2012) , our findings may not apply to females. 
Conclusions
In antipsychotic-treated males, a physiological postprandial suppression of serum prolactin appears absent. Marked variability in fasting prolactin levels may reflect individual variations in the diurnal cycle. In psychiatric practice, blood samples of prolactin are often obtained without considering diurnal variation or meal ingestion. Our data suggest that uniform acquisition procedures (e.g. morning sampling and fasting state) may enhance reliability of prolactin levels in antipsychotic-treated male patients. psychiatric outpatient clinics in the Capital Region of Copenhagen are thanked for all referred patients.
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